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Until recently the treatment of carcinoma of the 
prostate was limited either to radical prostatectomy 
by the perinea! or retropubic route, or to hormonal 
manipulation. Approximately 5% of all patients with 
this disease are suitable candidates for radical sur-
gery. Hormonal manipulation is palliative in nature 
and is generally used when there is evidence of meta-
static disease (in about 50% of patients). There thus 
remains a group of patients (40% to 45%) in whom 
the disease is localized, yet too extensive for surgical 
treatment, for whom definitive radiotherapy can play 
a major role. 
Pre-treatment Evaluation 
Once the histological diagnosis of carcinoma of 
the prostate has been made it is desirable to delineate 
the exact extent of disease in order to provide certain 
guidelines for optimal management and for predict-
ing prognosis. In an attempt to evaluate the various 
diagnostic procedures, we at the Medical College of 
Virginia are conducting an ongoing study where all 
patients with clinically localized prostatic carcinoma 
undergo the following work-up: 
1. Laboratory Studies 
a) WBC, hematocrit, platelets 
b) Total and prostatic fraction of acid phos-
phatase (blood is obtained either prior to 
or at least 24 hours after rectal examina-
tion). 
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c) Alkaline phosphatase and BUN. 
d) Bone marrow biopsy for histological ex-
amination, and radioimmunoassay for 
prostatic acid phosphatase. 
2. Radiological Studies 
a) Chest x-ray 
b) Intravenous pyelography 
c) Bipedal lymphangiogram 
d) 99m Tc Labeled di-phosphate bone scan 
Radiation Therapy 
Although the use of ionizing radiation in the 
treatment of carcinoma of the prostate was first re-
ported in 1911 by Pasteau, 1 the majority of reports 
have appeared within the last ten years. In a recent 
comprehensive review of the subject Ray and his 
colleagues 2 have documented clinical studies which 
collectively report on 880 cases in which external 
beam irradiation was the primary mode of treatment. 
They have concluded "that potentially tumoricidal 
dosage of irradiation can be delivered to the prostate 
with relative safety and in general the initial response 
of the local tumor to irradiation in survival rates at 
five years were encouraging." 
Results 
Local. In general , the reports of various authors 
support our experience that 70% to 80% of patients 
show marked resolution of the disease within six 
months on clinical examination. We do not, at the 
present, recommend post-treatment prostatic 
biopsies as a routine procedure. 
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Survival. On reviewing the results of various in-
vestigators dealing with the definitive treatment of 
adenocarcinoma of the prostate with megavoltage 
irradiation therapy, one finds that the five-year sur-
vival rate varies from 60% to 70% and the ten-year 
survival rate varies from 30% to 40%. Ray and his 
colleaguess from Stanford University have reported 
the results of treatment for two clinical groups of 
patients based upon the extent of the disease as deter-
mined by digital examination. In one group of pa-
tients the disease was limited to the prostate and this 
group of patients had a 71 % and 41 % survival rate at 
five and ten years respectively. In the other group of 
patients the disease had extracapsular extension and 
this group of patients had 41 % and 31 % survival rates 
at five and ten years respectively. Hillaris and his 
colleagues4 from Memorial Hospital have reported 
that all patients with intracapsular disease"Tf 1, T 2 , 
and Ts) and negative lymph nodes were alive and free 
of disease at five years while disease-free survival 
decreased to 70% in patients with extracapsular dis-
ease and negative nodes or in patients with intra-
capsular disease with positive nodes. Only 50% of 
patients with extensive local disease (Ts and T4 ) and 
positive nodes were alive without evidence of disease 
at five years. It has been my experience that dissemi-
nation of disease is more frequent in patients with a 
large primary tumor, with a high-grade tumor, and in 
the presence of histologically positive lymph nodes. 
In addition, there is rapid systemic dissemination of 
the disease once the para-aortic lymph nodes are 
involved. 
Present Area of Clinical Investigation 
The major cause of failure of definitive radio-
therapy in carcinoma of the prostate is the spread of 
tumor, outside the high dose of radiation field, either 
to the lymph nodes or to the bones. It is generally 
accepted that young patients (below 65 years), pa-
tients with a high-grade tumor and with diffuse in-
volvement of the prostate gland (multiple chips in-
volved, post-transurethral resection of the prostate) 
have a poor survival rate even when they present with 
early (stage A) disease. It remains to be seen whether 
definitive radiation therapy in this select group of 
patients with stage A carcinoma of the prostate will 
alter the natural history and provide an improved 
survival rate. 
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